Alzheimer's disease Other Imaging Findings
Alzheimer's disease Microchapters |
Diagnosis |
---|
Treatment |
Alzheimer's disease Other Imaging Findings On the Web |
American Roentgen Ray Society Images of Alzheimer's disease Other Imaging Findings |
Risk calculators and risk factors for Alzheimer's disease Other Imaging Findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to assess for any underlying condition. In these patients, use of amyloid β PET scan will reveal lower FDG (fluorine-18 fluorodeoxyglucose) metabolism and higher PiB ([11 C]Pittsburgh compound B) deposition in areas of the brain affected by Alzheimer's disease.
Other Imaging Findings
Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to further assess the patient for any underlying condition. The Amyloid Imaging Taskforce (AIT) recommends use of amyloid β (Aβ) positron emission tomography (PET) scanning in atypical cases of Alzheimer's. The tracer used in PET scan for amyloid β include [11 C]Pittsburgh compound B (PiB) and fluorine-18 fluorodeoxyglucose(FDG). Patients with greater decline in memory function have lower FDG metabolism and higher PiB deposition in areas of the brain affected by Alzheimer's disease. According to the guidelines of AIT, amyloid β PET scan is recommended in cases of:
- Patients with persistent or progressive unexplained mild cognitive impairment
- Patients with early age onset
- Patients with progressive dementia.